Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.14.5621

N-Acetyltransferase 2 Gene Polymorphisms are Associated with Susceptibility to Cancer: a Meta-analysis  

Tian, Fang-Shuo (Department of Epidemiology, School of Public Health, China Medical University)
Shen, Li (Department of Epidemiology, School of Public Health, China Medical University)
Ren, Yang-Wu (Department of Epidemiology, School of Public Health, China Medical University)
Zhang, Yue (Department of Epidemiology, School of Public Health, China Medical University)
Yin, Zhi-Hua (Department of Epidemiology, School of Public Health, China Medical University)
Zhou, Bao-Sen (Department of Epidemiology, School of Public Health, China Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.14, 2014 , pp. 5621-5626 More about this Journal
Abstract
N-acetyltransferase 2 (NAT2) is a polymorphic enzyme that plays an important role in the metabolism of various potential carcinogens. In recent years, a number of studies have been carried out to investigate the relationship between the rs1799930 and rs1799931 polymorphism in NAT2 and cancer risk in multiple populations for different types of cancer. However, the results were not consistent. Therefore, we performed a meta-analysis to further explore the relationship between NAT2 polymorphism and the risk of cancer. A total of 21 studies involving 15, 450 subjects for rs1799930 and 13, 011 subjects for rs1799931 were included in this meta-analysis. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess strength of associations. We also evaluated the publication bias and performed a sensitivity analysis. Overall, our results showed an apparent significant association between the NAT2 rs1799930 polymorphism and cancer susceptibility in Asians (GA vs. GG: OR=1.22, 95% CI=1.03-1.45; dominant model: OR=1.22, 95% CI=1.03-1.43) and population-based controls (GA vs. GG: OR=1.10, 95% CI=1.01-1.19; dominant model: OR=1.09, 95% CI=1.01-1.18). In contrast, a significant association was observed between the NAT2 rs1799931 G>A polymorphism and decreased cancer susceptibility in overall meta-analysis (AA vs. GG: OR=0.55, 95% CI=0.33-0.93; GA vs. GG: OR=1.00, 95% CI=0.88-1.14; dominant model: OR=0.97, 95% CI=0.86-1.10; recessive model: OR=0.56, 95% CI=0.34-0.94) and the Asian group (AA vs. GG: OR=0.50, 95% CI=0.26-0.94; recessive model, OR=0.50, 95% CI=0.27-0.94). We found that the NAT2 rs1799930 may be a risk factor, while the NAT2 rs1799931 polymorphism is associated with a decreased risk of cancer and is likely a protective factor against cancer development.
Keywords
NAT2; polymorphism; association; cancer susceptibility; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Cotterchio M, Boucher BA, Manno M, et al (2008). Red meat intake, doneness, polymorphisms in genes that encodecarcinogen-metabolizing enzymes and colorectal cancerrisk. Cancer Epidemiol Biomarkers Prev, 17, 3098-107.   DOI   ScienceOn
2 De Stefani E, Boffetta P, Mendilaharsu M, et al (1998). Dietary nitrosamines, heterocyclic amines, and risk of gastric cancer:a case-control study in Uruguay. Nutr Cancer, 30, 158-62.   DOI
3 Delort L, Satih S, Kwiatkowski F, et al (2010). Evaluation of breast cancer risk in a multigenic model including lowpenetrance genes involved in xenobiotic and estrogenmetabolisms. Nutr Cancer, 62, 243-51.   DOI
4 Demokan S, Suoglu Y, Gozeler M, et al (2010). N-acetyltransferase1 and 2 gene sequence variants and risk of head and neck cancer. Mol Biol Rep, 37, 3217-26.   DOI
5 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
6 Egger M, Davey Smith G, Schneider M, et al (1997). Bias inmeta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI   ScienceOn
7 Eichholzer M, Rohrmann S, Barbir A, et al (2012). Polymorphismsin heterocyclic aromatic amines metabolism-related genes are associated with colorectal adenoma risk. Int J Mol Epidemiol Genet, 3, 96-106.
8 Hein DW (1988). Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta, 948, 37-66.
9 Hein DW, Doll MA, Gray K, et al (1993). Metabolicactivation of N-hydroxy-2-aminofluorene and N-hydroxy­2-acetylaminofluorene by monomorphic N-acetyltransferase(NAT1) and polymorphic N-acetyltransferase (NAT2) incolon cytosols of Syrian hamsters congenic at the NAT2 locus. Cancer Res, 53, 509-14.
10 Majumdar S, Mondal BC, Ghosh M, et al (2008). Association of cytochrome P450, glutathione S-transferase and N-acetyltransferase 2 gene polymorphisms with incidence of acute myeloid leukemia. Eur J Cancer Prev, 17, 125-32.   DOI   ScienceOn
11 Mantel N, Haenszel W (1959). Statistical aspects of the analysisof data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
12 Muthusamy KA, Lian LH, Vairavan N, et al (2012). Genetic polymorphisms of EGF 5'-UTR and NAT2 857G/A associated with glioma in a case control study of Malaysian patients. Genet Mol Res, 11, 2939-45.   DOI
13 Nikishina MV, Vavilin VA, Makarova SI, et al (2007). Analysis of associations of NAT2 gene polymorphisms with the risk of lung cancer. Bull Exp Biol Med, 143, 83-6.   DOI
14 Osian G, Procopciuc L, Vlad L (2006). NAT2 gene polymorphismand sporadic colorectal cancer. Prevalence, tumor stage and prognosis. A preliminary study in 70 patients. J Gastrointestin Liver Dis, 15, 347-53.
15 Pande JN, Pande A, Singh SP (2003). Acetylator status, drug metabolism and disease. Natl Med J India, 16, 24-6.
16 Silveira VS, Canalle R, Scrideli CA, et al (2012). CYP3A5and NAT2 gene polymorphisms: role in childhood acutelymphoblastic leukemia risk and treatment outcome. Mol Cell Biochem, 364, 217-23.   DOI
17 Wang G, Hou J, Ma L, et al (2012). Risk factor for clear cell renal cell carcinoma in Chinese population: a case-control study. Cancer Epidemiol, 36, 177-82.   DOI
18 Windmill KF, Gaedigk A, Hall PM, et al (2000). Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci, 54, 19-29.   DOI
19 Al-Moundhri MS, Al-Kindi M, Al-Nabhani M, et al (2007).NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations. World J Gastroenterol, 13, 2697-702.   DOI
20 Agudo A, Bonet C, Sala N, et al (2013). Hemochromatosis (HFE)gene mutations and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Carcinogenesis, 34, 1244-50.   DOI
21 Balaji L, Krishna BS, Bhaskar LV (2012). An unlikely role for the NAT2 genotypes and haplotypes in the oral cancer of south Indians. Arch Oral Biol, 57, 513-8.   DOI
22 Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50,1088-101.   DOI   ScienceOn
23 Blum M, Grant DM, McBride W, et al (1990). Human arylamineN-acetyltransferase genes: isolation, chromosomallocalization and functional expression. DNA Cell Biol, 9,193-203.   DOI   ScienceOn
24 Borlak J, Reamon-Buettner SM (2006). N-acetyltransferase2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet, 7, 58.   DOI
25 Cleary SP, Cotterchio M, Shi E, et al (2010). Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes and colorectal cancer risk. Am J Epidemiol, 172, 1000-14.   DOI
26 Colditz GA, Burdick E, Mosteller F (1995). Heterogeneity in meta-analysis of data from epidemiologic studies: acommentary. Am J Epidemiol, 142, 371-82.
27 Hou YY, Ou HL, Chu ST, et al (2011). NAT2 slow acetylation haplotypes are associated with the increased risk of betelquid-related oral and pharyngeal squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 112,484-92.   DOI
28 Hickman D, Pope J, Patil SD, et al (1998). Expression ofarylamine N-acetyltransferase in human intestine. Gut, 42,402-9.   DOI
29 Hickman D, Risch A, Camilleri JP, et al (1992). Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics, 2, 217-26.   DOI
30 Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.   DOI   ScienceOn
31 Jang, JH, Cotterchio M, Borgida A, et al (2012). Genetic variantsin carcinogen-metabolizing enzymes, cigarette smoking andpancreatic cancer risk. Carcinogenesis, 33, 818-27.   DOI
32 Kwon HT, Ma GX, Gold RS, et al (2013). Primary care physicians'cancer screening recommendation practices and perceptions of cancer risk of Asian Americans. Asian Pac J Cancer Prev, 14, 1999-2004.   과학기술학회마을   DOI   ScienceOn
33 Landi S, Gemignani F, Moreno V, et al (2005). A comprehensiveanalysis of phase I and phase II metabolism genepolymorphisms and risk of colorectal cancer. PharmacogenetGenomics, 15, 535-46.
34 Le Marchand L, Sivaraman L, Franke AA, et al (1996). Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeablyin epidemiological studies? Cancer Epidemiol BiomarkersPrev, 5, 449-55.
35 Leiro-Fernandez V, Valverde D, Vazquez-Gallardo R, etal (2010). Genetic variations of NAT2 and CYP2E1and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics, 11, 1205-6.   DOI
36 Probst-Hensch NM, Haile RW, Ingles SA, et al (1995).Acetylation polymorphism and prevalence of colorectaladenomas. Cancer Res, 55, 2017-20.
37 Yamada S, Tang M, Richardson K, et al (2009). Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in adiverse population. Pharmacogenomics, 10, 1433-45.   DOI
38 Zanrosso CW, Emerenciano M, Faro A, et al (2012). Genetic variability in N-acetyltransferase 2 gene determinessusceptibility to childhood lymphoid or myeloid leukemia in Brazil. Leuk Lymphoma, 53, 323-7.   DOI
39 Zgheib NK, Shamseddine AA, Geryess E, et al (2013). Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women. Mutat Res, 747-748, 40-7.   DOI
40 Gemignani F, Landi S, Szeszenia-Dabrowska N, et al (2007). Development of lung cancer before the age of 50: the role ofxenobiotic metabolizing genes. Carcinogenesis, 28, 1287-93.   DOI   ScienceOn